Step by Step


3/19/2019 - Medical Grand Rounds - Systemic Sclerosis From Bedside to Bench - Lessons Learned from Recent Trials





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Recognize biomarkers in systemic sclerosis
  • Describe how different cell types cause fibrosis
  • Explain single cell RNA sequencing

Suggested Additional Reading:

  1. Tabib T, Morse C, Wang T, Chen W, Lafyatis R.  SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin. J Invet Dermatol. 2018; 138(4): 802-10. doi: 10.1016/j.jid.2017.09.045. PubMed PMID: 29080679.
  2.  Rice LM, Ziemek J, Stratton EA, McLaughlin SR, Padilla CM, Mathes AL, Christmann RB, Stifano G, Browning JL, Whitfield ML, Spiera RF, Gordon JK, Simms RW, Zhang Y, Lafyatis R. A longitudinal biomarker for the extent of skin  disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2015;67(11)3004-15. doi: 10.1002/art.39287. PubMed PMID: 26240058; PubMed Central PMCID: PMC5522178.
  3. Rice LM, Padilla CM, McLaughlin SR, Mathes A, ZIemek J, Goummih S, Nakerakanti S, York M, Farina G, Whitfield ML, Spiera RF, Christmann RB, Gordon JK, Weinberg J, Simms RW, Lafyatis R. Fresolimumab treatment decreases biomarkers and improves clinical symptoms sclerosis patients. J Clin Invest. 2015;125(7):2795-807. doi: 10.1172/JCI77958. PubMed 26098215; PubMed Central PMCID: PMC4563675.

Dinesh Khanna, MD, MSc — Professor of Medicine, Frederick G.L. Huetwell Professor of Rheumatology, Director, University of Michigan Scleroderma Program, Division of Rheumatology/Dept. of Internal Medicine.
No relationships with industry relevant to the content of this educational activity have been disclosed.
Robert Lafyatis, MD — Professor of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh
No relationships with industry relevant to the content of this educational activity have been disclosed.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.